Malignant glioma invasion is a primary cause of brain cancer treatment failure, yet the molecular mechanisms underlying its regulation remain elusive. We developed a novel functional-screening strategy and identified downregulated in renal cell carcinoma (DRR) as a regulator of invasion. We show that DRR drives invasion in vitro and in vivo. We found that while DRR is not expressed in normal glial cells, it is highly expressed in the invasive component of gliomas. Exploring underlying mechanisms, we show that DRR associates with and organizes the actin and microtubular cytoskeletons and that these associations are essential for focal adhesion (FA) disassembly and cell invasion. These findings identify DRR as a new cytoskeletal crosslinker that regulates FA dynamics and cell movement.
Introduction
Gliomas, the most common primary brain cancers, are among the most devastating of human malignancies (Louis et al., 2002) . Benign gliomas, known as pilocytic astrocytomas, are seen in children. They are very well treated by complete surgical resection, with patients typically maintaining a full life expectancy (Fernandez et al., 2003) . Malignant gliomas, known as astrocytomas, oligodendrogliomas, or glioblastomas, are adult neoplasms. They can be further divided into low grade and high grade. Low-grade gliomas are highly invasive, but have low proliferation rates, often invading multiple lobes before clinical presentation. Over time, low-grade gliomas incur genetic changes that convert them to a higher grade (Louis et al., 2002) . The distinguishing feature between benign and malignant gliomas is brain invasion; benign gliomas do not invade normal brain, whereas malignant gliomas are highly invasive (Kleihues and Cavenee, 2000) .
One approach to convert this devastating cancer into a more manageable one is to inhibit malignant glial cell (MGC) invasion; maintaining MGCs in a local environment leaves further treatment options open. The current understanding of cell invasion is a composite derived from studies of different cell types and environments (Friedl and Wolf, 2003; Ridley et al., 2003) . It includes the extension of a cellular process, attachment through focal adhesion (FA) formation, degradation of the extracellular matrix to create space to accommodate the moving cell, translocation of the cell body forward, and release of cell rear FAs (Friedl and Wolf, 2003) . This multistep process requires the coordinated action of cell surface receptors, signaling pathways, cytoskeletal elements, FA components, and extracellular matrix degrading enzymes (Burridge and Chrzanowska-Wodnicka, 1996; Lauuffenburger and Horwitz, 1996; Ridley et al., 2003) . Within this scheme, recent studies have pointed to the importance of actin/microtubule (MT) dynamics in both cell front membrane protrusion and cell rear retraction (Palazzo and Gundersen, 2002; Rodriguez et al., 2003) .
Cell rear retraction requires regulated FA disassembly (Friedl and Wolf, 2003) . Earlier studies have shown that the actin/MT system has an important function in the process (Kaverina et al., 1998 (Kaverina et al., , 1999 Krylyshkina et al., 2002 Krylyshkina et al., , 2003 Ezratty et al., 2005) ; however, the molecular mechanisms that underlie FA disassembly remain unclear. A recent study has shown that conditional loss of the spectraplakin, ACF7, leads to abnormalities in wound repair and defects in epidermal cell migration. ACF7 achieves these functions by coordinating actin/ MT dynamics to regulate FA turnover (Wu et al., 2008) .
Although there are many similarities between cell movement in normal physiologic conditions and in cancer, MGCs are thought to use additional or alternate mechanisms (Beadle et al., 2008) . Instead of using a movement paradigm similar to epithelial or mesenchymal cells, MGCs invade the dense substance of the brain using a mode of cell movement that is more similar to neural progenitor cell movement. To uncover molecular mechanisms that specifically regulate MGC invasion, we developed a novel forward genetic-screening method and identified downregulated in renal cell carcinoma (DRR) as a novel powerful promoter of MGC invasion. DRR was originally cloned from the short arm of chromosome 3 from patients with renal cell carcinoma (Wang et al., 2000) . Although a definitive function for this protein has not been reported, a function as a tumor suppressor has been suggested as heterologous expression reduced cell division (Wang et al., 2000) .
We show here that DRR drives MGC invasion in both in vitro and in vivo invasion assays. Importantly, we have clinically validated the importance of DRR; although DRR is not expressed in normal human brain glia, it is highly expressed in the invasive component of malignant gliomas. Thus, DRR expression in malignant gliomas correlates with invasion. We delved into the molecular mechanism through which DRR functions and uncovered that DRR associates with and organizes both the actin and MT cytoskeletons. By uncoupling this association, we show that DRR interaction with actin and MTs is essential for FA disassembly and cell invasion. Our findings suggest that DRR has an important function in glioma biology by augmenting FA dynamics, thus driving MGC invasion. Together, these findings identify DRR as a new and important cytoskeletal crosslinker that regulates FA dynamics and directional cell movement.
Results
Functional-screening assay identifies DRR as a promoter of invasion MGC invasiveness can be assayed using a 3D invasion model (Del Duca et al., 2004) . Using this model as a starting point, we developed a novel functionalscreening assay by retrovirally transducing MGCs, the U251 glioma cell line, to express an entire brain cDNA library. We reasoned that if we could make a cell heterologously express a gene that promotes invasion, it would be distinguishable from other cells as a hyperinvasive cell. Tumor spheroids were generated from these transduced MGCs and their invasiveness was assessed in the 3D invasion model. Distinguishable hyperinvasive cells were then captured and expanded in culture and the originally transduced gene was identified ( Figure 1a) . DRR was identified as a strong promoter of invasion using this forward genetic approach.
To test whether or not DRR acts as an effector of MGC invasion, we generated composite tumor spheroids made up of both DRR overexpressing MGCs (DRR þ ; Supplementary Figure S1 ) and wild-type (WT) MGCs and studied the invasion parameters of each cell line (Figures 1b-e Figure S1 ) causes a significant decrease in invasion (Figures 1f, g, Figure S2 ). An elongated spindle cell shape has been shown to be the preferred mode of MGC movement through brain (Beadle et al., 2008) .
We next examined DRR's function as an invasion promoter in a mouse model. DRR þ and DRR À tumors were implanted into the subcallosal/caudate region of mice and invasion was assessed (Figures 1l and m) . DRR À tumors grow as a well-circumscribed mass without invasion into the adjacent parenchyma, and these cells have a round morphology. Conversely, DRR þ tumors are highly invasive. These invasive cells, which are distinguished by their large, hyperchromatic and elongated nuclei, have an elongated shape, separate from the tumor mass, invade parenchyma, and, importantly, move toward and into the corpus callosum. Invasion into white matter tracts such as the corpus callosum is a preferred invasion paradigm used by human malignant glial tumors (Pedersen et al., 1995 Figure S1B and C), suggesting a decrease in cell proliferation as earlier described (Wang et al., 2000) . We assessed the function of DRR in cell division and also found that cell division is inversely correlated with DRR expression (Figure 1n ). The notion that MGC invasion and proliferation are temporally exclusive events has been described (Giese et al., 1996) . Our data show that we have developed a robustscreening strategy to identify molecules that drive cell invasion. Using this assay, we have identified DRR as a candidate regulator of cell movement. We have validated this finding in both in vitro and in vivo invasion assays thus confirming that DRR is an important molecule in cell invasion.
DRR is expressed in neurons and human gliomas but not in normal glia
To clinically validate our in vitro and in vivo findings, we set out to determine the expression pattern of DRR in normal human brain and malignant gliomas. We found that in normal human brain DRR is strongly expressed in neurons, but not in astrocytes or in oligodendrocytes (Figures 2a-f ; see Supplementary Figure S3 for highmagnification images). Colabeling of cultured embryonic rat neurons and glia with neuronal and glial markers also shows that DRR is expressed in neurons, but not in glial cells . DRR antibody controls including antigenic peptide competition, immunolabeling with preimmune serum, and single secondary antibody immunolabeling were negative. Analysis of DRR expression in eight malignant gliomas of each grade indicates that DRR is highly but not uniformly expressed in all malignant glial tumors (Figures 2m). Grade 2 and 3 gliomas, which are highly invasive tumors with low proliferation rates, uniformly express DRR. In contrast, grade 4 gliomas, which are both highly invasive and highly proliferative, express DRR in a suggestive pattern. The invasive peripheral tumor cells uniformly express DRR, whereas the central proliferative tumor region showed variability in DRR expression. The central tumor in 5/8 grade 4 gliomas showed little to no DRR expression, whereas the central tumor was DRR positive in 3/8 tumors. Taken together, these data show that although DRR is not expressed in normal glial cells, it has a robust and differential expression pattern in malignant gliomas. 
DRR associates with the cytoskeleton
To uncover how DRR functions to drive cell movement, we began by localizing DRR at the subcellular level.
Endogenous or heterologously expressed DRR predominantly localizes along actin stress fibers, FAs, and membrane ruffles (Figure 3a ). In agreement with an earlier report (Wang et al., 2000) , DRR can also be found in the nucleus (Supplementary Figure S5) . These results suggest that DRR could be promoting invasion through a direct influence on the cytoskeletal apparatus or through a regulatory function in the nucleus.
To address this issue, we sought to uncouple DRR from the actin cytoskeleton by identifying minimal domains required for actin association. To do so, we generated sequential N-and C-terminal truncated constructs of human DRR and assayed for localization using fluorescent tags. Two minimal regions capable of actin association were identified, amino acids 62-100 and 108-120 (Supplementary Figure S7) . We then speculated that cytoskeletal association would be a property of DRR that would be conserved across species and, therefore, domains required for actin association would also be conserved across species. We identified and mutated the amino acids within the 62-100 and 108-120 regions that were conserved across human, mouse, rat, and zebrafish DRR (Supplementary Figure S6) . We found that the combined mutation of the conserved PE motifs to alanines in both segments (DRR DPEPE ) leads to a significant perturbation of the actin cytoskeleton and abolishes actin association with the remaining stress fibers (Figure 3a) .
Along the same line, we also wanted to learn more about DRR's mechanism of action by identifying molecules that affect DRR association with the cytoskeleton. We used yeast two-hybrid screening of normal brain libraries to identify DRR-binding partners. The light chain (LC2) subunit of MAP1A was identified as a candidate DRR-binding protein. Indeed, we found that DRR and LC2 colocalize along actin stress fibers and membrane ruffles, and can be coimmunoprecipitated when heterologously expressed (Figures 3b and c) , suggesting their association. Interestingly, mutation of the DRR-actin-binding sites seems to increase DRR association with LC2 ( Figure 3b) . We also found, in some cells, that the non-actin-binding form of DRR (DRR DPEPE ) can localize to MTs (data not shown). We then developed non-LC2-binding forms of DRR using truncation and amino-acid mutagenesis analysis. A minimal N-terminal HRE sequence was found to be required for LC2 binding (Figure 3b ). When this region was mutated, DRR DHRE , there is a significant perturbation of the actin cytoskeleton and the localization pattern of DRR changes. There is an increase in DRR expression in the nucleus and diffuse cytoplasmic localization (Figure 3a) . We also observed slight actin association. In summary, these data show that DRR localizes to the actin cytoskeleton, FAs, and nucleus. We defined minimal regions required for actin association (DRR DPEPE ), identified the LC2 subunit of MAP1A as a DRR-associated protein, and determined that this association could be disrupted by mutation of the amino-terminal HRE region (DRR DHRE ).
DRR association with the cytoskeleton is required for cell movement
The ability to disrupt the DRR-actin and DRR-LC2 associations provides two methods to determine whether DRR association with the cytoskeleton is required to drive cell movement. We thus generated stable cell lines expressing DRR DPEPE or DRR DHRE and tested their invasiveness in a 3D invasion assay. We found that loss of the DRR-actin association leads to a Bthreefold reduction in invasion compared with WT cells, suggesting that this mutant form of DRR is acting as a functional dominant negative (Figure 4) . A similar finding is also seen when the DRR-LC2 interaction is disrupted (Figure 4) . Together, these data show that DRR association with actin and LC2 is required to drive cell invasion.
DRR regulates FA dynamics
The process of cell movement requires regulated FA dynamics (Lauuffenburger and Horwitz, 1996; Friedl and Wolf, 2003) . To determine whether DRR expression affects FAs, we expressed a GFP-paxillin fusion protein and studied the effect of DRR expression on FA dynamics using confocal videomicroscopy ( Figure 5 ). In non-polarized DRR þ cells, we found that the total time taken for FAs to form and disassemble is 40.05±3.00 min (Figures 5a-c) . The rate constant for GFP-paxillin incorporation into FAs was (6.2 ± 0.9) Â 10 À3 per min and the rate constant for GFP-paxillin disassembly was (8.6±0.7) Â 10 À3 per min. Conversely, FAs were not dynamic in WT control cells. We were unable to detect FAs that formed or disassembled within the 170 min imaging interval (Figure 5d ). These data strongly support a mechanism whereby DRR drives cell invasion by enhancing FA dynamics.
It has been established that FA disassembly requires polymerized MTs (Kaverina et al., 1998 (Kaverina et al., , 1999 Krylyshkina et al., 2002 Krylyshkina et al., , 2003 Ezratty et al., 2005) . As we have shown that DRR interacts with the LC2 subunit of MAP1A and that DRR overexpression leads to less stable FAs, we wanted to examine directly whether DRR promotes FA disassembly.
One way to examine MT control of FA disassembly is to disassemble MTs using the microtubular depolymerizing agent nocodazole. After nocodazole application, FAs increase in size as there are no MTs available for disassembly. On nocodazole washout, MTs polymerize 
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and FAs disassemble (Ezratty et al., 2005) . When this experiment was performed using DRR þ and DRR À cells plated on the extracellular matrix component fibronectin, two striking findings were observed. First, on nocodazole application and MT depolymerization, DRR þ cells develop more and larger FAs compared with non-treated cells (Figure 6a ). In contrast, we did not observe differences in FA number and size in nocodazole treated versus non-treated DRR À cells (Figure 6a; Supplementary Figure S8 ). The findings that DRR expression promotes FA disassembly whereas DRR deficiency leads to stable mature FAs point to DRR as a novel regulator of FA dynamics.
DRR organizes the actin and microtubular cytoskeletons
The results from the FA disassembly assay suggest that DRR association with both the actin cytoskeleton and the LC2 subunit of MAP1A are required for FA disassembly (Figure 6 ). One mechanism through which DRR could achieve this result is to alter MT dynamics by placing MTs in the vicinity of FAs (Kaverina et al., 1999) . We tested this hypothesis and found that DRR regulates both the MT and actin cytoskeletons. DRR expression leads to a highly organized MT system that strongly parallels the localization pattern of the actin cytoskeleton (Figure 7a ). In contrast, DRR deficiency leads to an irregular, poorly organized MT cytoskeleton that does not parallel the actin cytoskeleton (Figure 7b ). DRR deficiency also leads to a profound change in the actin cytoskeleton with loss of stress fiber formation and the promotion of a cortical actin system (Figures 7a and  b) . The promotion of a stress fiber actin system allows for actomyosin contraction and thus cell rear retraction (Verkhovsky et al., 1995) . Importantly, we also found that DRR expression is required for MTs to reach FAs. MTs in DRR-deficient cells do not approach FAs (Figure 7b ). In contrast, DRR expression leads to a close association between MTs and FAs (Figure 7a) . Together, these data strongly suggest that DRR is a novel regulator of FA dynamics by controlling both the actin and MT cytoskeletons (Figure 7c ).
Discussion
MGC invasion into normal brain is a defining feature of malignant gliomas and is directly related to the aggressive nature of these cancers. Many molecules have been implicated in malignant glioma invasion (Salhia et al., 2006; Johnston et al., 2007; Wang et al., 2008) , but the molecular mechanisms that regulate MGC invasion remain elusive. This study shows a novel functional-screening assay to identify promoters of invasion. Using this assay, we identified DRR as an invasion promoter. We show here that DRR promotes MGC invasion in 3D in vitro and in mouse models of invasion. Importantly, characterization of DRR expression in normal human brain and gliomas reveals that in normal brain DRR is abundantly expressed in neurons, but not in glia. In contrast, DRR is uniformly and highly expressed in the invasive regions of both low-and high-grade gliomas, whereas its expression in the central proliferative region of high-grade gliomas is variable. Together, these findings implicate DRR as an important regulator of glioma invasion and suggest that DRR may be useful as a biomarker to delineate invasive regions and grade malignant gliomas.
A recent study has linked DRR and malignant gliomas, reporting that DRR expression is reduced in high-grade gliomas compared with low-grade gliomas, whereas expression in normal brain was not described (van den Boom et al., 2006) . We believe that our work supports and expands on this report and could be explained by the anti-proliferative function of DRR shown here and reported elsewhere (Wang et al., 2000) . We interpret our results in the following way: low-grade gliomas express DRR and thus exhibit an invasive phenotype. Over time, a subpopulation of these cancer cells develops additional genetic alterations, which include loss of DRR expression, converting low-grade gliomas to a higher grade. The loss of DRR expression leads to high cell proliferation, as is seen in the central tumor region of high-grade gliomas. In this scheme, DRR not only drives cell invasion, it can also regulate cell proliferation. This implicates DRR as a central player in glioma biology, possibly acting as a molecular switch that converts invasive low-grade gliomas to their high-grade proliferative counterparts. More work will be required to address this possibility. Indeed, it has been shown that invasion and division are temporally exclusive events in MGCs (Giese et al., 1996) .
Cell invasion requires a cycle of events that uses both the actin cytoskeleton and MTs along with the continuous formation and disassembly of FAs. The function of MTs in FA turnover has been well established (Kaverina et al., 1998 (Kaverina et al., , 1999 Krylyshkina et al., 2002 Krylyshkina et al., , 2003 Ezratty et al., 2005) . More recently, FAs have been postulated to be the site of actin and MT crosstalk (Rodriguez et al., 2003) . Accumulating evidence suggests that MTs grow toward FAs in a process that is coordinated by F-actin. Much less is known about the constituents of FAs in normal glial cells and gliomas, and the molecular mechanisms that regulate FA turnover in normal glial cells and gliomas have not been described. However, a recent study reported that the Rho effector mDia1 (mammalian homologue of the Drosophila gene Diaphanous 1) has a function in FA turnover by localizing c-SRC to FAs in the C6 glioma cell line, possibly through actin association (Yamana et al., 2006) .
Our study provides evidence in support of the view that MTs facilitate FA disassembly and identifies DRR as a new player in this normal physiologic process. We show here that DRR is a novel actin/MT crosslinker that regulates FA disassembly. We propose that DRR links the actin and MT cytoskeletons by directly or indirectly interacting with actin and indirectly interacting with MTs by associating with the LC2 subunit of MAP1A (Figure 7c ). In support, we show that DRR localizes to the actin cytoskeleton and FAs and interacts with the LC2 subunit MAP1A. We show that DRR expression organizes both the actin and MT cytoskeletons so that MTs approach FAs and promote their disassembly. DRR deficiency, or the disruption of this complex by abolishing DRR-actin or DRR-LC2 association, leads to a loss of coordination between actin and MTs, as well as the inability of MTs to reach FAs.
These findings translate into important consequences for cancer cell invasion. We propose that the de novo expression of DRR observed in invasive MGCs leads to more rapid FA disassembly and thus invasion. The inability of MGCs to separate from the tumor mass when the DRR-actin association is abolished has clinical implications. Indeed, a CD151-specific metastasis blocking monoclonal antibody has been shown to inhibit metastasis by preventing cell rear retraction and thus cell detachment and migration from the primary tumor mass (Zijlstra et al., 2008) . Future studies will be needed to identify potential anti-invasive chemotherapeutic targets within the DRR-associated macromolecular complex.
Finally, we observed that DRR expression converts cells from a round to an elongated spindle shape, reminiscent of that recently shown to be the preferred mode of MGC invasion and similar to the mode of cell movement used by neural progenitor cells (Beadle et al., 2008) . Significant progress has been made toward understanding the origins of brain cancers with recent data pointing toward neural progenitor cells (Dirks, 2008) . Our findings that DRR, in normal brain, is expressed in neurons but not glia adds further intrigue to this notion. In the normal physiologic condition, is DRR an effector of neuronal migration? Is there an oncogenic event that triggers its de novo expression in brain cancer, or, is it expressed in the early neural progenitor cells that may be the origins of these cancers? Future work is necessary to answer these questions.
Materials and methods
Functional-screening assay A normal human adult brain cDNA library (Clontech, Mountain View, CA, USA) was subcloned into the pLib retroviral vector (Clontech) and used to transfect the PT67 packaging cell line using Lipofectamine PLUS reagent (Clontech). The secreted replication deficient retrovirus was collected from the supernatent 24-72 h post-transfection and used to consecutively transduce, over a 72 h time course, the WT-U251 glial cell line (Figure 1a ). , and DRR þ cells were cultured in DMEM high-glucose supplemented with 10% FBS and a penicillin-streptomycin antibiotic mixture. Human glioblastoma cell line (U87MG) (Cavanee lab, University of California at San Diego) was grown in DMEM high-glucose supplemented with 10% inactivated FBS and a penicillin-streptomycin antibiotic mixture.
Human glioma analysis
Cell proliferation, migration, and invasion assays See Supplemental Information for details.
Mouse intracerebral tumor implantation
All animal experimentation was approved by the Institution's Animal Care Committee and conformed to the guidelines of the Canadian Council of Animal Care. Six-week-old CD1 nu/nu athymic mice (Charles River, Canada) were anesthetized by an intraperitoneal injection containing Ketamine, Xylazine, and Acepromazine.
Yeast two-hybrid screening Yeast two-hybrid screens were performed using the Matchmaker Two-Hybrid System 3 (Clontech). Full-length DRR was used as the bait to screen a human brain cDNA library (Clontech).
Immunocytochemistry
Cells were grown on glass coverslips or on fibronectin (10 mg/ ml)-coated coverslips, fixed with 4% PFA and permeabilized with 0.5% Triton X-100 before being immunolabeled. The FA disassembly assay was performed as described earlier (Ezratty et al., 2005) . Briefly, cells were incubated in serum-free media for 24 h before being treated with nocodazole (10 mM; 4 h). The drug was washed out along a variable time course (5, 15, 30, and 60 min) using serum-free media. Fluorescently labeled cells were visualized with a Zeiss 510 confocal microscope (63 Â objective). The number and surface area of vinculinstained FAs were quantified using Image J software. At least 10 fields from three independent experiments were quantified.
Confocal videomicroscopy WT or DRR
þ cells were seeded on 35 mm glass bottom culture dishes (MatTek Corporation) before being transfected with GFP-paxillin; 24-48 h post-transfection, the images were captured every 1 min for 170 min using a Zeiss 510 confocal microscope (63 Â objective). Five DRR þ and five control (WT) cells were analyzed, a total of 17 FAs were analyzed for DRR þ cells. The apparent rate constants for the incorporation of GFP-paxillin into FAs and its disassembly from FAs was quantified using the technique described in Webb et al., 2004. Measurements were obtained from five cells, 5-10 FAs/cell. In control cells, no FAs were identified that assembled or disassembled within the 170 min imaging interval. Data is presented as mean ± standard error.
